What AI Integration Means for an Existing Healthtech Product
Adding an AI feature to an existing digital health product is a materially different exercise from adding an AI feature to a general SaaS product. The existing product has an established GDPR compliance framework, existing data flows that regulators and NHS data governance teams have approved, and potentially an existing MHRA classification and DTAC evidence base. An AI integration that changes how patient data flows, changes the nature of outputs the product produces, or changes the product's intended purpose can affect all three. The first question to address before any AI integration scoping is whether the proposed feature changes the MHRA classification of the product. If the existing product is not a medical device, does the AI feature make it one? If it is already a medical device, does the AI feature change its risk class? These are not hypothetical concerns. The MHRA's position on AI-augmented software is that the AI component's intended purpose is assessed in the context of the overall software's intended purpose. Adding an AI feature that performs a clinical function to an administrative tool can reclassify the whole product. The second question is whether the AI integration changes the GDPR compliance picture. If the existing product processes patient health data under Article 9(2)(h) for healthcare purposes, adding an AI feature that sends that data to a third-party model provider requires a data processing agreement with that provider and an assessment of whether the transfer is compatible with the original legal basis. We address both questions as part of the integration scoping, before any code is written.
Our Integration Process for Existing Healthtech Products
We begin with a regulatory impact assessment for the proposed AI feature. This reviews the existing product's MHRA classification status, DTAC evidence base, and GDPR compliance framework, and assesses the impact of the proposed AI integration on each. The regulatory impact assessment is not a lengthy separate engagement. It is a structured review session that produces a clear picture of what the integration requires beyond the technical implementation. Once the regulatory impact is understood, the technical integration scoping covers the AI capability, the data flows from the existing product into the AI component, the model selection rationale, the explainability requirements, the confirmation gates or safety mechanisms required, and the monitoring approach. We review the existing codebase before the scoping session, as we do for all integration engagements. Understanding the existing data model, the existing clinical data flows, and the existing compliance controls before scoping means we can identify conflicts and constraints before they affect the build. Development integrates the AI capability within the existing product architecture, extending rather than replacing the existing compliance and safety framework. GDPR controls for the AI data flow are implemented as an extension of the existing compliance framework. The AI feature's audit trail integrates with the existing product's clinical audit log. The explainability layer for clinician-facing outputs follows the same design patterns as the existing product's interface. We do not introduce a parallel architecture or a new compliance framework. We extend what already exists.
Deliverables for a Healthtech AI Integration
At handover, you receive the AI integration deployed within your existing product, with source code, updated compliance documentation, and an updated DTAC evidence contribution. The updated compliance documentation covers the GDPR impact of the AI integration: the updated data flow map, the data processing agreements with any new third-party processors, the updated record of processing activities, and the supplementary DPIA for the AI processing activities. The MHRA classification assessment documents whether the AI integration changes the product's regulatory classification, with the reasoning applied using the MHRA DENI framework. If the classification changes, we document what that means for the product's regulatory obligations. The updated DTAC evidence contribution documents how the AI feature affects each of the five DTAC domains: clinical safety, including whether the AI integration requires an update to the clinical safety case; data protection, covering the updated GDPR controls; technical security, covering the AI component's security controls; interoperability, if the AI integration affects NHS system connections; and usability, with the clinical user testing evidence for the AI feature. The evaluation harness covers clinical scenario testing for the AI feature: a defined set of clinical inputs with expected outputs, which verifies the AI feature's behaviour after subsequent code changes or model version updates. Monitoring integration tracks AI feature usage, latency, error rates, and the clinical safety metrics relevant to the feature's intended purpose.
Regulatory Impact of Adding AI to an Existing Clinical Product
The most important thing a healthtech founder needs to understand before adding AI to an existing product is that the regulatory impact assessment is not optional. The MHRA's position is clear: the regulatory classification of a software product is determined by its intended purpose. If adding an AI feature changes the intended purpose in a way that meets the medical device definition, the product's regulatory status changes. Similarly, the DTAC evidence base that you submitted for the existing product may no longer be accurate once an AI feature is added. An NHS trust that has already completed DTAC assessment of your product may require a re-assessment if the AI integration materially changes the product's clinical function or data processing. The ICO's position on AI and GDPR requires a fresh Data Protection Impact Assessment for AI processing activities that involve personal data, even when a DPIA was already completed for the existing product's data processing. The AI processing introduces new risks, including the risk of AI outputs that infringe data subject rights, that the original DPIA did not assess. We complete the regulatory impact assessment as part of every AI integration scoping for existing healthtech products. The cost of this assessment is included in the fixed price. The alternative, discovering the regulatory impact after the AI feature is built and deployed, is substantially more expensive in terms of both cost and timeline.
Patient Data Safety in AI Integration
The patient data safety considerations for AI integration in a healthtech product go beyond GDPR compliance. NHS organisations and clinical governance teams will ask specific questions about how patient data is handled within the AI component that go further than standard data protection questions. Does the AI model provider train on patient data submitted via the API? Most major providers offer data processing agreements that include assurances against training on API inputs, but these need to be verified for the specific provider and the specific API endpoint being used. Is patient data retained by the model provider after inference? Providers have different retention policies for API inputs, and for NHS patient data the retention period must be appropriate to the clinical context. Where is the inference computation performed? NHS data with specific data residency requirements, particularly data subject to NHS Digital data sharing agreements, may require UK-based or at minimum UK-sovereign inference. Does the AI integration introduce a new attack surface for patient data? The prompt injection risk in clinical AI systems is real: if the AI processes patient-generated text, a malicious patient could potentially craft input that extracts or corrupts other patient data. We assess and address each of these questions as part of the integration architecture design, not as a post-launch review.
Why Healthtech Founders Choose SpeedMVPs for AI Integration
The healthtech founders who engage SpeedMVPs for AI integration into an existing product have typically encountered one of two situations. The first is a technical team that is competent in the existing product's technology but does not have the clinical AI or healthcare regulatory expertise to design an AI integration that will pass NHS clinical governance review. They build the AI feature correctly from a technical perspective but create compliance and governance problems that block NHS deployment. The second is a founder who has received conflicting advice about the regulatory impact of their proposed AI feature and needs an independent expert assessment before committing to the integration. We resolve both situations with a clear process: regulatory impact assessment first, technical integration scoping second, build third. This sequencing ensures that the technical decisions are made with full regulatory awareness, rather than having to reverse them later because the regulatory assessment contradicts the technical approach. Our specific experience with MHRA classification, DTAC assessment criteria, and NHS Digital data security requirements means the regulatory assessment is accurate rather than generic. Our fixed-price model means the cost of the compliance-first approach is not punitive. Get a free consultation at speedmvps.co.uk